We showed a lack of association of the APOBEC3B deletion with breast and/or ovarian risk (for the first time including familial breast cancer), which was independently validated in three European cohorts (in total: 2972 cases and 3682 controls). This evidence concerns the gene APOBEC3B and breast cancer.